- Global Pharma News & Resources

Global Myasthenia Gravis Market Outlook to 2026 - A $3.65 Billion Opportunity, Hindered by Limited Availability of FDA Approved Drugs & Costly Treatment Options -

The "Myasthenia Gravis - Global Market Outlook (2017-2026)" report has been added to's offering.

According to this report, the Global Myasthenia Gravis market accounted for $1,215 million in 2017 and is expected to reach $3,651.25 million by 2026 growing at a CAGR of 13% during the forecast period.

Increasing health care spending & improving health care infrastructure, increase in occurrence of autoimmune disorders and strong pipeline in its treatment are some of the key factors propelling the market growth.

However, limited availability of FDA approved drugs and costly treatment options are some issues restricting the market growth.

Amongst treatment, drug treatment segment commanded considerable market share in the global market owing to the factors responsible for modifying the immune response of the immune system by inhibition of white blood cell activity.

Based on geography, Asia Pacific region is expected to register highest market growth rate during the forecast period. Due to Several non-governmental and governmental organizations in the region are concerned in organizing awareness programs

Treatments Covered:

  • Rapid Immunotherapies
  • Drug Treatment

Companies Profiled:

  • Novartis
  • Takeda Pharmaceutical Company Limited
  • Grifols
  • Valeant Pharmaceuticals International
  • Alexion Pharmaceutical
  • F. Hoffmann-La Roche
  • CSL Behring
  • Baxter International
  • Avadel Pharmaceuticals (Flamel Technologies)
  • Shire

For more information about this report visit

View source version on

Editor Details

Last Updated: 21-Jan-2019